MaxCyte MXCT Business Segments — Cost of Goods Sold
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by MaxCyte in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about MaxCyte's business segments — cost of goods sold.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is MaxCyte's business segments — cost of goods sold?
- MaxCyte (MXCT) reported business segments — cost of goods sold of $1.57M in Q1 2026.
- How has MaxCyte's business segments — cost of goods sold changed year-over-year?
- MaxCyte's business segments — cost of goods sold increased by 4.8% year-over-year, from $1.5M to $1.57M.
- What is the long-term trend for MaxCyte's business segments — cost of goods sold?
- Over 2 years (2023 to 2025), MaxCyte's business segments — cost of goods sold has grown at a 14.5% compound annual growth rate (CAGR), from $4.74M to $6.22M.
- What does business segments — cost of goods sold mean?
- Includes the direct costs attributable to the production of instruments and the delivery of services within the cell engineering segment. This metric is essential for evaluating the direct efficiency of the manufacturing and service delivery processes.